It seems that the major concern that this company has had is "navigating the current reimbursement landscape." In other words, the company is still having issues with reimbursement on their product. A few months ago TSB wrote a post about Life Spine and TSON collaborating in the hope of propping up TSON's sales bag. Has this helped the company? Or, was this an error in judgement? Tick Tock, Tick, Tock. Is TSON on the clock? Could this be another Hydrocision in the making? TSB wants to know what our readers think?
One final question: Why are these small companies compelled to expand their operational facilities at a time when they need to conserve as much capital in an uncertain market with concerns regarding reimbursement. You know the old Chinese proverb: "No money, no funny."